江苏恩华药业股份有限公司 2017 年第三季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2017-032 江苏恩华药业股份有限公司 2017 年第三季度报告正文 1 江苏恩华药业股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,319,850,888.97 | | 2,974,889,940.25 | 11.60% | | 归 ...

江苏恩华药业股份有限公司 2017 年半年度报告全文 江苏恩华药业股份有限公司 2017 年半年度报告 2017 年 07 月 1 江苏恩华药业股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 请投资者注意阅读并关注以下重大风险： 1、产品招标风险。2017 年尚未招标的省份将陆续开展药品招标工作，但是 各省份的招标方案和实际执行依然存在着很大的不确定性，这将对公司部分近 年上市的新产品的销售造成影响。 2、药品降价风险。由于各地招标过程中价格仍然是中标的关键因素，这将 造成投标企业间竞相压价，这会造成公司参与招标的产品存在降价的风险，给 公司的未来增长带来不 ...

江苏恩华药业股份有限公司 2017 年第一季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2017-016 江苏恩华药业股份有限公司 2017 年第一季度报告正文 1 江苏恩华药业股份有限公司 2017 年第一季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 第一节 重要提示 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 838,300,742.74 | 758,919,365.69 | 10.46% | | 归属 ...

江苏恩华药业股份有限公司 2016 年年度报告全文 江苏恩华药业股份有限公司 2016 年年度报告 2017 年 02 月 1 江苏恩华药业股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异，注意投资风险。 请投资者注意阅读并关注以下重大风险： 1、产品招标风险。2017 年尚未招标的省份将陆续开展药品招标工作，但是 各省份的招标方案和实际执行依然存在着很大的不确定性，这将对公司部分近 年上市的新产品的销售造成影响。 2、药品降价风险。由于各地招标过程中价格仍然是中标的关键因素，这将 造成投标企业间竞相 ...

江苏恩华药业股份有限公司 2016 年第三季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2016-061 一、主要会计数据和财务指标 江苏恩华药业股份有限公司 2016 年第三季度报告正文 1 江苏恩华药业股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,882,403,939.67 | 2,550,922,408. ...

江苏恩华药业股份有限公司 2016 年半年度报告全文 江苏恩华药业股份有限公司 2016 年半年度报告 2016 年 07 月 1 江苏恩华药业股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 2 | 目录 | | --- | | 2016 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 20 | | 第五节 | 重要事项 26 | | 第六节 | ...

江苏恩华药业股份有限公司 2016 年第一季度报告正文 证券代码：002262 证券简称：恩华药业 公告编号：2016-021 江苏恩华药业股份有限公司 2016 年第一季度报告正文 1 江苏恩华药业股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏恩华药业股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 758,919,365.69 | 674,832,087.12 | 12.46% | | 归属于上市公司股东的净利润（元） | 70,265,337.24 | 60,042,756. ...

江苏恩华药业股份有限公司 2015 年年度报告全文 江苏恩华药业股份有限公司 2015 年年度报告 2016 年 02 月 1 江苏恩华药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人孙彭生、主管会计工作负责人高爱好及会计机构负责人(会计主 管人员)胡吉瑞声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，不构成公司对投资者的 实质承诺，敬请投资者注意投资风险。 1、产品招标风险。2016 年尚未招标的省份将陆续开展药品招标工作，各地 招标方案和实际执行依然存在着很大的不确定性，各地招标过程中价格仍然是 中标的关键因素，这将造成投标企业间竞相压价，公司在争取到更多市场份额 的同时，亦会造成部分品种毛利率的下降。 2、市场竞争格局发生变化的风险。国家基本药物目录调整将带来市场竞争 格局的变化，导致市场竞争变化的不确定性，也会给公司的增长带来 ...

[Important Notice](index=2&type=section&id=Item%201.%20Important%20Notice) The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content, assuming legal responsibility for any false statements, misleading representations, or major omissions - The company's head, Sun Pengsheng, chief accountant, Gao Aihao, and head of accounting, Hu Jirui, declare that the financial statements in the quarterly report are true, accurate, and complete[4](index=4&type=chunk) [Key Financial Data and Shareholder Changes](index=3&type=section&id=Item%202.%20Key%20Financial%20Data%20and%20Shareholder%20Changes) The company's total assets and net assets attributable to shareholders significantly increased, with steady growth in operating revenue and net profit, while net cash flow from operating activities decreased [Key Accounting Data and Financial Indicators](index=3&type=section&id=Item%202.1.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) At the end of the reporting period, the company's total assets and net assets attributable to shareholders of the listed company showed significant year-on-year growth, with operating revenue and net profit also achieving steady increases, while net cash flow from operating activities decreased, and basic and diluted earnings per share improved Key Accounting Data and Financial Indicators (Balance Sheet Section) | Indicator | End of Reporting Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 2,609,460,869.80 | 1,922,656,263.98 | 35.72% | | Net Assets Attributable to Shareholders of Listed Company | 1,772,165,599.39 | 1,043,287,238.27 | 69.86% | Key Accounting Data and Financial Indicators (Income Statement and Cash Flow Statement Section) | Indicator | Current Reporting Period (RMB) | Change from Prior Year Same Period | Year-to-Date (RMB) | Year-to-Date Change from Prior Year Same Period | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 680,857,844.76 | 10.81% | 2,025,174,180.09 | 10.51% | | Net Profit Attributable to Shareholders of Listed Company | 69,533,623.78 | 18.53% | 215,884,867.21 | 18.39% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 69,285,836.04 | 18.11% | 215,326,800.73 | 18.09% | | Net Cash Flow from Operating Activities | -- | -- | 97,255,513.06 | -17.08% | | Basic Earnings Per Share (RMB/share) | 0.1433 | 18.53% | 0.4450 | 18.41% | | Diluted Earnings Per Share (RMB/share) | 0.1433 | 18.53% | 0.4450 | 18.41% | | Weighted Average Return on Net Assets | 5.76% | -0.34% | 19.01% | -0.83% | Non-recurring Gains and Losses Items and Amounts | Item | Year-to-Date Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 11,490.27 | | | Government Subsidies Recognized in Current Profit and Loss | 300,000.00 | | | Other Non-operating Income and Expenses Apart from the Above | 464,969.24 | | | Less: Income Tax Impact | 153,728.51 | | | Impact on Minority Interests (After Tax) | 64,664.52 | | | Total | 558,066.48 | -- | [Total Number of Shareholders and Top Ten Shareholders' Holdings at the End of the Reporting Period](index=4&type=section&id=Item%202.2.%20Total%20Shareholders%20and%20Top%20Ten%20Holdings) As of the end of the reporting period, the company had 10,279 common shareholders, with Xuzhou Enhua Investment Co., Ltd. being the largest shareholder at 40.09% ownership, and the actual controllers collectively holding 60.95% of the company's shares through direct and indirect means, acting in concert Total Number of Common Shareholders at the End of the Reporting Period | Total Number of Common Shareholders at the End of the Reporting Period | | :--- | | 10,279 | Top 10 Common Shareholders' Holdings | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held | Number of Restricted Shares Held | Pledge or Freeze Status | Quantity | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Xuzhou Enhua Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 40.09% | 194,503,039 | 0 | | | | Sun Pengsheng | Domestic Natural Person | 4.77% | 23,127,085 | 17,345,313 | | | | Qi Chao | Domestic Natural Person | 4.45% | 21,613,848 | 16,210,385 | Pledge | 15,600,000 | | Chen Zengliang | Domestic Natural Person | 3.96% | 19,196,438 | 14,397,328 | | | | Fu Qing | Domestic Natural Person | 3.96% | 19,196,436 | 14,397,326 | | | | Yang Ziliang | Domestic Natural Person | 3.72% | 18,044,440 | 13,533,330 | | | | Li Wei | Domestic Natural Person | 2.59% | 12,550,000 | 0 | | | | China Merchants Bank Co., Ltd. - Huatiamfu Medical Service Flexible Allocation Mixed Securities Investment Fund | Other | 2.43% | 11,809,102 | 0 | | | | Goldman, Sachs & Co. | Overseas Legal Person | 1.96% | 9,494,934 | 0 | | | | Ma Wusheng | Domestic Natural Person | 1.42% | 6,876,944 | 0 | | | Top 10 Unrestricted Common Shareholders' Holdings | Shareholder Name | Number of Unrestricted Common Shares Held | Share Type | Quantity | | :--- | :--- | :--- | :--- | | Xuzhou Enhua Investment Co., Ltd. | 194,503,039 | RMB Common Shares | 194,503,039 | | Li Wei | 12,550,000 | RMB Common Shares | 12,550,000 | | China Merchants Bank Co., Ltd. - Huatiamfu Medical Service Flexible Allocation Mixed Securities Investment Fund | 11,809,102 | RMB Common Shares | 11,809,102 | | Goldman, Sachs & Co. | 9,494,934 | RMB Common Shares | 9,494,934 | | Ma Wusheng | 6,876,944 | RMB Common Shares | 6,876,944 | | Sun Pengsheng | 5,781,772 | RMB Common Shares | 5,781,772 | | Qi Chao | 5,403,463 | RMB Common Shares | 5,403,463 | | GF Securities Co., Ltd. Customer Credit Trading Guarantee Securities Account | 4,804,734 | RMB Common Shares | 4,804,734 | | Chen Zengliang | 4,799,110 | RMB Common Shares | 4,799,110 | | Fu Qing | 4,799,110 | RMB Common Shares | 4,799,110 | - Sun Pengsheng, Qi Chao, Fu Qing, Chen Zengliang, and Yang Ziliang collectively hold **68.91%** of Xuzhou Enhua Investment Co., Ltd. and **20.86%** of the company, directly and indirectly controlling **60.95%** of the company's shares, making them the actual controllers and having signed a "Cooperation Agreement" to act in concert[11](index=11&type=chunk) [Significant Matters](index=6&type=section&id=Item%203.%20Significant%20Matters) During the reporting period, the company experienced significant changes in various financial indicators, primarily driven by private placement, changes in settlement methods, increased R&D investment, and higher market promotion expenses [Changes and Reasons for Major Accounting Statement Items and Financial Indicators](index=6&type=section&id=Item%203.1.%20Changes%20in%20Major%20Financial%20Items%20and%20Reasons) During the reporting period, the company's financial indicators underwent significant changes, primarily due to the completion of a private placement, changes in settlement methods, increased R&D investment, and higher market promotion expenses, leading to substantial growth in monetary funds, total assets, capital reserves, and total equity attributable to the parent company - Monetary funds increased by **73.45%** at the end of the period compared to the beginning, mainly due to the proceeds from the private placement completed during the reporting period[14](index=14&type=chunk) - Notes receivable increased by **160.03%** at the end of the period compared to the beginning, primarily due to changes in settlement methods during the reporting period[14](index=14&type=chunk) - Other receivables increased by **297.14%** at the end of the period compared to the beginning, mainly due to advances for marketing personnel's promotion and business expenses, and prepaid R&D expenses during the reporting period[14](index=14&type=chunk) - Inventories increased by **29.35%** at the end of the period compared to the beginning, primarily due to increased stocking during the reporting period[14](index=14&type=chunk) - Construction in progress increased by **35.08%** at the end of the period compared to the beginning, mainly due to increased fixed asset investments in Jiawang Industrial Park and Tongshan Industrial Park[14](index=14&type=chunk) - Total assets increased by **35.72%** at the end of the period compared to the beginning, primarily due to the proceeds from the private placement completed during the reporting period[14](index=14&type=chunk) - Short-term borrowings decreased by **34.68%** at the end of the period compared to the beginning, mainly due to the company repaying part of its bank loans with its own funds during the reporting period[14](index=14&type=chunk) - Accounts payable increased by **29.60%** at the end of the period compared to the beginning, primarily due to increased purchases of inventory goods during the reporting period[14](index=14&type=chunk) - Capital reserves increased by **4,519.27%** at the end of the period compared to the beginning, mainly due to the impact of the private placement completed during the reporting period[14](index=14&type=chunk) - Total equity attributable to the parent company increased by **69.86%** at the end of the period compared to the beginning, primarily due to the private placement completed and increased net profit during the reporting period[14](index=14&type=chunk) - Administrative expenses increased by **26.61%** year-on-year, mainly due to increased R&D investment, staff salaries, and depreciation during the reporting period[15](index=15&type=chunk) - Cash received relating to other operating activities decreased by **43.89%** in the current period compared to the same period last year, mainly due to a decrease in deposits received by subsidiaries during the reporting period[15](index=15&type=chunk) - Cash paid to and for employees increased by **33.37%** in the current period compared to the same period last year, mainly due to an increase in employees and higher employee salaries during the reporting period[15](index=15&type=chunk) - Cash paid relating to other operating activities increased by **39.95%** in the current period compared to the same period last year, mainly due to increased market development, maintenance, and academic promotion expenses during the reporting period[15](index=15&type=chunk) - Net cash flow from investing activities decreased by **112.54%** in the current period compared to the same period last year, mainly due to increased payments for the acquisition of fixed assets and wealth management products during the reporting period[15](index=15&type=chunk) - Net cash flow from financing activities increased by **1,303.31%** in the current period compared to the same period last year, mainly due to the proceeds from the private placement completed during the reporting period[15](index=15&type=chunk) - Net increase in cash and cash equivalents increased by **300.31%** in the current period compared to the same period last year, mainly due to the proceeds from the private placement completed during the reporting period[15](index=15&type=chunk) [Progress, Impact, and Solutions of Significant Matters](index=6&type=section&id=Item%203.2.%20Progress%2C%20Impact%2C%20and%20Solutions%20of%20Significant%20Matters) During the reporting period, the company had no significant matters requiring disclosure regarding their progress, impact, or solutions - The company had no significant matters requiring explanation of their progress, impact, or solutions during the reporting period[16](index=16&type=chunk) [Commitments by the Company or Shareholders Holding 5% or More](index=6&type=section&id=Item%203.3.%20Commitments%20by%20Company%20or%20Major%20Shareholders) The company and its major shareholders strictly fulfilled various commitments during the reporting period, including avoiding horizontal competition, preventing related parties from harming other shareholders' interests through related transactions, not occupying company funds, and ensuring the company's independent operation, with actual controllers also committing not to terminate their acting-in-concert agreement for three years and some shareholders pledging not to reduce their holdings within specific periods Fulfillment Status of Commitments | Commitment Reason | Promising Party | Commitment Content | Commitment Date | Commitment Period | Fulfillment Status | | :--- | :--- | :--- | :--- | :--- | :--- | | Commitments Made During Asset Restructuring | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to avoid horizontal competition | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to prevent related parties from harming other shareholders' interests through related transactions | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment regarding fund occupation | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Commitments Made During Initial Public Offering or Refinancing | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang; Xuzhou Enhua Investment Co., Ltd. | Commitment to ensure the company's independent operation | July 23, 2008 | Long-term Valid | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Chen Zengliang; Fu Qing; Qi Chao; Sun Pengsheng; Yang Ziliang | Not to reduce company shares within the next six consecutive months | September 04, 2014 | 6 months | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Sun Pengsheng; Qi Chao; Fu Qing; Chen Zengliang; Yang Ziliang | Commitment not to terminate the acting-in-concert agreement within the next three years | March 18, 2015 | 3 years | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Company Directors, Supervisors, Senior Management | Commitment regarding share trading during tenure | July 23, 2008 | During tenure and within twelve months after six months of resignation declaration | Strictly Fulfilled During Reporting Period | | Other Commitments Made to Small and Medium Shareholders | Xuzhou Enhua Investment Co., Ltd. and Company Directors, Supervisors, Senior Management | Not to reduce company shares within the next 6 months from the announcement date | July 09, 2015 | 6 months | Strictly Fulfilled During Reporting Period | [2015 Annual Operating Performance Forecast](index=8&type=section&id=Item%203.4.%202015%20Annual%20Performance%20Forecast) The company forecasts a **15.00% to 35.00%** increase in net profit attributable to shareholders of the listed company for 2015, ranging from **RMB 256.76 million to RMB 301.41 million**, primarily driven by stable growth in main business revenue 2015 Annual Operating Performance Forecast | Indicator | Change Range | Change Range (RMB 10,000) | 2014 Net Profit (RMB 10,000) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | 15.00% To 35.00% | 25,676 To 30,141 | 22,327 | - The main reason for the performance change is the stable growth in the company's main business revenue[19](index=19&type=chunk) [Securities Investment Status](index=8&type=section&id=Item%203.5.%20Securities%20Investment) The company had no securities investments during the reporting period - The company had no securities investments during the reporting period[20](index=20&type=chunk) [Holdings in Other Listed Companies](index=8&type=section&id=Item%203.6.%20Holdings%20in%20Other%20Listed%20Companies) The company did not hold equity in any other listed companies during the reporting period - The company did not hold equity in any other listed companies during the reporting period[21](index=21&type=chunk)

[Item I. Important Notice, Table of Contents and Definitions](index=2&type=section&id=Item%20I.%20Important%20Notice%2C%20Table%20of%20Contents%20and%20Definitions) This section provides essential preliminary information, including the table of contents and definitions relevant to the report [Item II. Company Profile](index=5&type=section&id=Item%20II.%20Company%20Profile) This section outlines the company's fundamental corporate information and recent registration changes [I. Company Overview](index=5&type=section&id=I.%20Company%20Overview) This section provides the company's basic industrial and commercial information, including its stock ticker "Enhua Pharmaceutical", stock code "002262", and full Chinese and English names, along with the legal representative Company Basic Information | Item | Information | | :--- | :--- | | Stock Abbreviation | Enhua Pharmaceutical | | Stock Code | 002262 | | Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Jiangsu Enhua Pharmaceutical Co., Ltd. | | Legal Representative | Sun Pengsheng | [III. Other Matters](index=5&type=section&id=III.%20Other%20Matters) During the reporting period, the company's registered address changed to No. 18 Yangshan Road, Xuzhou Economic Development Zone, while information disclosure channels remained unchanged - The company's registered address changed to No. 18 Yangshan Road, Xuzhou Economic Development Zone[17](index=17&type=chunk) - The company completed the industrial and commercial change registration on April 17, 2015[20](index=20&type=chunk) [Item III. Summary of Accounting Data and Financial Indicators](index=7&type=section&id=Item%20III.%20Summary%20of%20Accounting%20Data%20and%20Financial%20Indicators) This section presents a concise overview of the company's key financial performance and position for the reporting period [I. Key Accounting Data and Financial Indicators](index=7&type=section&id=I.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In the first half of 2015, the company achieved operating revenue of **CNY 1.344 billion**, an increase of **10.36%**, and net profit attributable to shareholders of **CNY 146.35 million**, up **18.33%**; total assets and net assets significantly grew due to private placement, while net cash flow from operating activities decreased by **30.36%** Key Accounting Data and Financial Indicators | Indicator | Current Reporting Period | Prior Year Period | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,344,316,335.33 | 1,218,169,942.77 | 10.36% | | Net Profit Attributable to Shareholders (CNY) | 146,351,243.43 | 123,683,030.80 | 18.33% | | Net Cash Flow from Operating Activities (CNY) | 45,097,525.94 | 64,755,329.95 | -30.36% | | Basic Earnings Per Share (CNY/share) | 0.3017 | 0.2549 | 18.36% | | **Indicator** | **End of Current Reporting Period** | **End of Prior Year** | **Year-on-Year Change** | | Total Assets (CNY) | 2,661,814,964.44 | 1,922,656,263.98 | 38.44% | | Net Assets Attributable to Shareholders (CNY) | 1,702,631,975.61 | 1,043,287,238.27 | 63.20% | [III. Non-Recurring Gains and Losses and Amounts](index=7&type=section&id=III.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **CNY 310,278.74**, primarily from government subsidies, disposal of non-current assets, and other non-operating income and expenses Non-Recurring Gains and Losses | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 25,599.14 | | Government Grants Included in Current Profit/Loss | 300,000.00 | | Other Non-Operating Income and Expenses | 152,297.77 | | Less: Income Tax Impact | 105,440.14 | | Less: Impact on Minority Interests (After Tax) | 62,178.03 | | **Total** | **310,278.74** | [Item IV. Board of Directors' Report](index=9&type=section&id=Item%20IV.%20Board%20of%20Directors'%20Report) This section details the company's operational performance, business analysis, core competencies, investment activities, and profit distribution plans for the reporting period [I. Overview](index=9&type=section&id=I.%20Overview) In the first half of 2015, the company achieved stable operating performance despite complex market and policy pressures, with operating revenue growing by **10.36%**, total profit by **18.02%**, and net profit attributable to parent by **18.33%** - In the first half of 2015, the company actively responded to policy pressures such as drug bidding, secondary price negotiations, and medical insurance cost control, maintaining market advantages in core areas and regions[31](index=31&type=chunk) Key Performance Indicators | Indicator | Amount (CNY) | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | 1,344,316,335.33 | 10.36% | | Total Profit | 172,131,198.14 | 18.02% | | Net Profit Attributable to Parent | 146,351,243.43 | 18.33% | [II. Analysis of Main Business](index=9&type=section&id=II.%20Analysis%20of%20Main%20Business) The company's main business grew steadily, though revenue growth was below the **15%** annual target due to external factors, yet total profit and net profit exceeded **50%** of the annual plan, with significant increases in financial expenses and R&D investment - The company's revenue growth in the first half of the year was lower than expected, mainly due to external factors such as medical insurance cost control, product price reductions, and drug bidding, but profit completion exceeded expectations[35](index=35&type=chunk) Key Expense and Cash Flow Items | Expense Item | Current Reporting Period (CNY) | Year-on-Year Change | Primary Reason | | :--- | :--- | :--- | :--- | | Financial Expenses | 8,329,941.18 | 59.42% | Increase in bank borrowings | | R&D Investment | 27,438,868.08 | 25.66% | Increased R&D investment | | Net Cash Flow from Financing Activities | 547,887,797.11 | 3,193.99% | Proceeds from non-public issuance of shares | [III. Composition of Main Business](index=10&type=section&id=III.%20Composition%20of%20Main%20Business) The company's main business comprises industrial and commercial segments, with the industrial segment being the primary profit driver due to its high gross margin of **74.08%**, and core products like anesthetic and psychiatric drugs contributing over **80%** of industrial revenue with gross margins around **80%** Main Business by Industry Segment | Industry Segment | Operating Revenue (CNY) | Gross Margin | Year-on-Year Revenue Change (CNY) | | :--- | :--- | :--- | :--- | | Industrial | 700,531,896.24 | 74.08% | +80,092,752.60 | | Commercial | 634,495,956.40 | 5.12% | +42,627,118.41 | Main Business by Product Category | Product Category | Operating Revenue (CNY) | Gross Margin | Year-on-Year Revenue Change (CNY) | | :--- | :--- | :--- | :--- | | Anesthetics | 312,515,900.25 | 83.49% | +27,523,834.46 | | Psychiatric Drugs | 253,360,223.89 | 79.86% | +38,149,673.89 | | Neurological Drugs | 32,710,726.44 | 56.96% | +8,842,122.58 | [IV. Analysis of Core Competencies](index=11&type=section&id=IV.%20Analysis%20of%20Core%20Competencies) The company's core competencies include its unique focus on central nervous system drugs, strong R&D capabilities, an integrated production model from raw materials to finished products, and an established marketing network - The company is the only pharmaceutical enterprise in China focused on the research and development and production of central nervous system drugs, possessing a national-level enterprise technology center and a research team of nearly **200** people[39](index=39&type=chunk) - In the first half of 2015, **CNY 27.44 million** was invested in R&D, resulting in **1** clinical approval, **5** clinical and production applications, and **10** patent authorizations (including **1** US patent)[40](index=40&type=chunk)[41](index=41&type=chunk) - The company possesses a complete production process from raw material synthesis to finished drug preparations, with this integrated model ensuring high operating profit margins[41](index=41&type=chunk)[42](index=42&type=chunk) [V. Analysis of Investment Status](index=12&type=section&id=V.%20Analysis%20of%20Investment%20Status) During the reporting period, the company had no external equity or securities investments, with its most significant investment being the completion of a private placement raising **CNY 537 million** net, primarily for an international API export base, drug preparation workshop, marketing network, and working capital, with **CNY 107 million** cumulatively invested by period-end - The company completed a non-public offering in June 2015, raising a total of **CNY 551 million** and a net amount of **CNY 537 million**[53](index=53&type=chunk) Committed Investment Projects from Raised Funds | Committed Investment Project | Adjusted Total Investment (CNY 10,000) | Cumulative Investment by Period-End (CNY 10,000) | Investment Progress | | :--- | :--- | :--- | :--- | | International API Export Base Construction Project | 22,886 | 10,480 | 45.79% | | Drug Preparation Manufacturing 5 Workshop Project | 12,200 | 193 | 1.58% | | Marketing Network Construction Project | 5,055 | 0 | 0.00% | | Supplementary Working Capital Project | 13,517.07 | 0 | 0.00% | | **Total** | **53,658.07** | **10,673** | **19.89%** | [VI. Forecast of Operating Performance for January-September 2015](index=17&type=section&id=VI.%20Forecast%20of%20Operating%20Performance%20for%20January-September%202015) The company anticipates a **15% to 35%** year-on-year increase in net profit attributable to shareholders for January-September 2015, driven by stable growth in its main business revenue 2015 January-September Performance Forecast | Item | Forecast Situation | | :--- | :--- | | Net Profit Change Range | 15.00% to 35.00% | | Net Profit Range (CNY 10,000) | 20,970 to 24,617 | | Net Profit for Same Period in 2014 (CNY 10,000) | 18,235 | | Reason for Performance Change | Stable growth in main business revenue | [IX. Implementation of Profit Distribution During the Reporting Period](index=17&type=section&id=IX.%20Implementation%20of%20Profit%20Distribution%20During%20the%20Reporting%20Period) The company implemented its 2014 profit distribution plan, distributing a cash dividend of **CNY 0.60** per **10** shares and **2.0** bonus shares per **10** shares to all shareholders, with no profit distribution planned for the first half of 2015 - The 2014 profit distribution plan included a cash dividend of **CNY 0.6** per **10** shares (tax inclusive) and **2** bonus shares per **10** shares (tax inclusive)[67](index=67&type=chunk) - For the first half of 2015, the company plans not to distribute cash dividends, send bonus shares, or convert capital reserves into share capital[69](index=69&type=chunk) [Item V. Significant Matters](index=19&type=section&id=Item%20V.%20Significant%20Matters) This section details the company's significant contracts, guarantees, and commitments made by the company or its major shareholders [VIII. Significant Contracts and Their Performance](index=20&type=section&id=VIII.%20Significant%20Contracts%20and%20Their%20Performance) During the reporting period, the company had no significant entrustment, contracting, or leasing contracts, with all external guarantees provided to subsidiaries, totaling **CNY 134 million** in actual outstanding guarantees at period-end, representing **7.89%** of net assets, all for subsidiaries with a debt-to-asset ratio exceeding **70%** Guarantee Information | Guarantee Situation | Amount (CNY 10,000) | | :--- | :--- | | Total Approved Guarantee Limit for Subsidiaries at Period-End | 37,000 | | Total Actual Guarantee Balance for Subsidiaries at Period-End | 13,426 | | Proportion of Total Actual Guarantees to Company's Net Assets | 7.89% | | Debt Guarantees Provided for Guaranteed Parties with Debt-to-Asset Ratio Exceeding 70% | 13,426 | [IX. Commitments Made by the Company or Shareholders Holding 5% or More Shares During or Prior to the Reporting Period and Continuing into the Reporting Period](index=23&type=section&id=IX.%20Commitments%20Made%20by%20the%20Company%20or%20Shareholders%20Holding%205%25%20or%20More%20Shares%20During%20or%20Prior%20to%20the%20Reporting%20Period%20and%20Continuing%20into%20the%20Reporting%20Period) The company's controlling shareholder and actual controllers consistently fulfilled commitments regarding avoiding horizontal competition, reducing related-party transactions, and not occupying company funds, with the five actual controllers also committing not to terminate their concerted action agreement for three years from March 18, 2015 - Controlling shareholder Enhua Investment and actual controller Sun Pengsheng, among others, continued to fulfill commitments to avoid horizontal competition and reduce related-party transactions[96](index=96&type=chunk)[97](index=97&type=chunk) - The company's five actual controllers (Sun Pengsheng, Qi Chao, Fu Qing, Chen Zengliang, and Yang Ziliang) signed a commitment on March 18, 2015, not to terminate their concerted action agreement within the next three years[97](index=97&type=chunk) [Item VI. Changes in Shareholding and Shareholder Information](index=26&type=section&id=Item%20VI.%20Changes%20in%20Shareholding%20and%20Shareholder%20Information) This section details the changes in the company's share capital and provides an overview of its shareholder structure [I. Changes in Shareholding](index=26&type=section&id=I.%20Changes%20in%20Shareholding) During the reporting period, the company's total share capital increased from **393 million** shares to **485 million** shares due to the implementation of the 2014 profit distribution plan, which included a **2-for-10** bonus share issuance, adding **78.624 million** shares, and a private placement of **13.423 million** new shares - Due to bonus shares and a non-public offering, the company's total share capital increased from **393,120,000** shares to **485,166,833** shares[105](index=105&type=chunk) - Share capital changes resulted from: **78,624,000** bonus shares and **13,422,833** new shares from a non-public offering[105](index=105&type=chunk)[106](index=106&type=chunk) [II. Number of Shareholders and Shareholding Information](index=27&type=section&id=II.%20Number%20of%20Shareholders%20and%20Shareholding%20Information) As of the end of the reporting period, the company had **8,879** common shareholders, with controlling shareholder Xuzhou Enhua Investment Co., Ltd. holding **40.09%**, and the five actual controllers collectively controlling **62.68%** of the company's shares through direct and indirect holdings - As of the end of the reporting period, the total number of common shareholders was **8,879**[110](index=110&type=chunk) Top Ten Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Xuzhou Enhua Investment Co., Ltd. | Domestic Non-State-Owned Legal Person | 40.09% | 194,503,039 | | Sun Pengsheng | Domestic Natural Person | 4.77% | 23,127,085 | | Qi Chao | Domestic Natural Person | 4.45% | 21,613,848 | | Chen Zengliang | Domestic Natural Person | 3.96% | 19,196,438 | | Fu Qing | Domestic Natural Person | 3.96% | 19,196,436 | | Yang Ziliang | Domestic Natural Person | 3.72% | 18,044,440 | - Sun Pengsheng, Qi Chao, Fu Qing, Chen Zengliang, and Yang Ziliang are parties acting in concert and are the company's actual controllers, directly and indirectly controlling **62.68%** of the company's shares[110](index=110&type=chunk)[111](index=111&type=chunk) [Item VII. Information on Preferred Shares](index=31&type=section&id=Item%20VII.%20Information%20on%20Preferred%20Shares) This section confirms the absence of preferred shares during the reporting period [Preferred Shares](index=31&type=section&id=Preferred%20Shares) During the reporting period, the company had no preferred shares - The company had no preferred shares during the reporting period[116](index=116&type=chunk) [Item VIII. Information on Directors, Supervisors, and Senior Management](index=32&type=section&id=Item%20VIII.%20Information%20on%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) This section details the changes in shareholdings of the company's directors, supervisors, and senior management [I. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=32&type=section&id=I.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the company's directors, supervisors, and senior management did not reduce their shareholdings, with many seeing an increase in their holdings due to the implementation of bonus shares, such as Chairman Sun Pengsheng's shares increasing from **19.27 million** to **23.13 million** - During the reporting period, the shareholdings of directors, supervisors, and senior management increased due to bonus shares, with no share reductions[118](index=118&type=chunk) Shareholding Changes of Directors, Supervisors, and Senior Management | Name | Position | Shares Held at Beginning of Period (shares) | Shares Increased During Period (shares) | Shares Held at End of Period (shares) | | :--- | :--- | :--- | :--- | :--- | | Sun Pengsheng | Chairman | 19,272,571 | 3,854,514 | 23,127,085 | | Qi Chao | Vice Chairman | 18,011,540 | 3,602,308 | 21,613,848 | | Fu Qing | Director; Deputy General Manager | 15,997,030 | 3,199,406 | 19,196,436 | | Chen Zengliang | Director; Deputy General Manager | 15,997,031 | 3,199,407 | 19,196,438 | | Yang Ziliang | Director; Deputy General Manager | 15,037,033 | 3,007,407 | 18,044,440 | [Item IX. Financial Report](index=33&type=section&id=Item%20IX.%20Financial%20Report) This section encompasses the company's financial statements, including the audit report, balance sheets, income statements, cash flow statements, and notes to the financial statements [I. Audit Report](index=33&type=section&id=I.%20Audit%20Report) The company's 2015 semi-annual financial report was not audited - The company's semi-annual financial report was unaudited[121](index=121&type=chunk) [II. Financial Statements](index=33&type=section&id=II.%20Financial%20Statements) This section presents the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2015, prepared in accordance with Chinese Enterprise Accounting Standards [III. Basic Information of the Company](index=52&type=section&id=III.%20Basic%20Information%20of%20the%20Company) The company, formerly Jiangsu Enhua Pharmaceutical Group Co., Ltd., was restructured into a joint-stock company in 2007, with its registered capital increasing to **CNY 485.17 million** during the reporting period due to bonus shares and a private placement, operating in the pharmaceutical and medical device wholesale industry with a business scope covering the manufacturing and sales of psychiatric and anesthetic drugs - During the reporting period, the company implemented a "2 bonus shares for every 10 shares" plan and completed a non-public offering of **13,422,833** shares[160](index=160&type=chunk)[161](index=161&type=chunk) - Following the share capital changes, the company's registered capital increased from **CNY 393 million** to **CNY 485 million**[161](index=161&type=chunk) [VII. Notes to Consolidated Financial Statements](index=69&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed explanations of key items in the consolidated financial statements, including cash and cash equivalents, accounts receivable, construction in progress, short-term borrowings, and operating revenue and costs [1. Cash and Cash Equivalents](index=69&type=section&id=1.%20Cash%20and%20Cash%20Equivalents) At period-end, the company's total cash and cash equivalents amounted to **CNY 888 million**, a significant increase from **CNY 407 million** at the beginning of the period, primarily due to proceeds from the non-public offering, with **CNY 110 million** being restricted funds such as bank acceptance bill deposits Cash and Cash Equivalents | Item | Balance at Period-End (CNY) | Balance at Beginning of Period (CNY) | | :--- | :--- | :--- | | Cash on Hand | 3,534,015.52 | 601,268.87 | | Bank Deposits | 774,754,364.45 | 296,156,876.99 | | Other Cash and Cash Equivalents | 109,672,762.03 | 110,601,573.64 | | **Total** | **887,961,142.00** | **407,359,719.50** | [3. Accounts Receivable](index=71&type=section&id=3.%20Accounts%20Receivable) At period-end, the book value of accounts receivable was **CNY 645 million**, with a gross balance of **CNY 679 million** and a bad debt provision of **CNY 34.03 million**, with **98.12%** of receivables being current (within 1 year) Accounts Receivable | Category | Gross Balance at Period-End (CNY) | Bad Debt Provision at Period-End (CNY) | Book Value at Period-End (CNY) | | :--- | :--- | :--- | :--- | | Provisioned by Credit Risk Characteristics | 665,850,001.20 | 22,829,395.29 | 643,020,605.91 | | Individually Provisioned for Immaterial Amounts | 12,741,577.41 | 11,201,057.40 | 1,540,520.01 | | **Total** | **678,591,578.61** | **34,030,452.69** | **644,561,125.92** | [9. Construction in Progress](index=79&type=section&id=9.%20Construction%20in%20Progress) At period-end, the book value of construction in progress was **CNY 370 million**, an increase of approximately **CNY 75 million** from the beginning of the period, with major projects including Jiawang Industrial Park (**CNY 272 million**) and Xincheng Logistics Park (**CNY 42 million**), both still under construction Construction in Progress | Project Name | Budget (CNY) | Balance at Period-End (CNY) | Project Progress | Funding Source | | :--- | :--- | :--- | :--- | :--- | | Jiawang Industrial Park | 400,000,000.00 | 272,206,205.68 | 68.05% Unfinished | Raised Funds | | Xincheng Logistics Park | 120,000,000.00 | 42,005,478.26 | 47.61% Unfinished | Other | | Tongshan New District Industrial Park | 143,000,000.00 | 32,293,236.95 | 100.00% Completed | Raised Funds | | **Total** | **691,062,189.69** | **370,427,174.98** | -- | -- | [27. Operating Revenue and Operating Cost](index=89&type=section&id=27.%20Operating%20Revenue%20and%20Operating%20Cost) In the first half of 2015, the company generated total operating revenue of **CNY 1.344 billion**, with the main business contributing the vast majority at **CNY 1.335 billion**, and total operating cost amounting to **CNY 784 million** Operating Revenue and Operating Cost | Item | Revenue (CNY) | Cost (CNY) | | :--- | :--- | :--- | | Main Business | 1,335,027,852.64 | 783,612,963.09 | | Other Business | 9,288,482.69 | 798,464.22 | | **Total** | **1,344,316,335.33 | **784,411,427.31** | [XIII. Supplementary Information](index=107&type=section&id=XIII.%20Supplementary%20Information) This section provides details on non-recurring gains and losses, as well as calculations for Return on Equity (ROE) and Earnings Per Share (EPS), with the weighted average ROE attributable to common shareholders being **13.25%** and basic EPS at **CNY 0.3017** for the reporting period Key Financial Ratios | Profit for the Reporting Period | Weighted Average Return on Net Assets | Basic Earnings Per Share (CNY/share) | Diluted Earnings Per Share (CNY/share) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders of the Company | 13.25% | 0.3017 | 0.3017 | | Net Profit Attributable to Common Shareholders of the Company After Deducting Non-Recurring Gains and Losses | 13.22% | 0.3010 | 0.3010 | [Item X. List of Documents for Reference](index=109&type=section&id=Item%20X.%20List%20of%20Documents%20for%20Reference) This section lists all supporting documents available for review, ensuring transparency and accessibility of information